Optimal prophylaxis of chemotherapy-induced nausea and vomiting for moderately emetogenic chemotherapy: a meta-analysis

References

• 1 Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 73, 249–262 (2013).
  Medline CASGoogle Scholar
• 2 Antiemesis (version 2): NCCN clinical practice guidelines in oncology (2016). www.nccn.org/professionals/physician_gls/default.aspx#antiemesis.
  Google Scholar
• 3 MASCC/ESMO antiemetic guideline (2016). www.mascc.org/antiemetic-guidelines.
  Google Scholar
• 4 Arpornwirat W, Albert I, Hansen VL, Levin J, Bandekar RR, Grunberg SM. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer 115, 5807–5816 (2009).
  Medline CASGoogle Scholar
• 5 Tanioka M, Kitao A, Matsumoto K et al. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br. J. Cancer 109, 859–865 (2013).
  Medline CASGoogle Scholar
• 6 Ito Y, Karayama M, Inui N et al. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer 84, 259–264 (2014).
  MedlineGoogle Scholar
• 7 Maehara M, Ueda T, Miyahara D et al. Clinical efficacy of aprepitant in patients with gynecological cancer after chemotherapy using paclitaxel and carboplatin. Anticancer Res. 35, 4527–4534 (2015).
  Medline CASGoogle Scholar
• 8 Yahata H, Kobayashi H, Sonoda K et al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int. J. Clin. Oncol. 21(3), 491–497 (2016).
  Medline CASGoogle Scholar
• 9 Hesketh PJ, Schnadig ID, Schwartzberg LS et al. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer 122, 2418–2425 (2016).
  Medline CASGoogle Scholar
• 10 Hesketh PJ, Wright O, Rosati G et al. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support. Care Cancer 20, 1471–1478 (2012).
  MedlineGoogle Scholar
• 11 Kitayama H, Tsuji Y, Sugiyama J, Doi A, Kondo T, Hirayama M. Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study. Int. J. Clin. Oncol. 20, 1051–1056 (2015).
  Medline CASGoogle Scholar
• 12 Nishimura J, Satoh T, Fukunaga M et al. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled Phase 3 trial. Eur. J. Cancer 51, 1274–1282 (2015).
  Medline CASGoogle Scholar
• 13 Aridome K, Mori SI, Baba K et al. A Phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients. Mol. Clin. Oncol. 4, 393–398 (2016).
  Medline CASGoogle Scholar
• 14 Zhang Y, Yang Y, Zhang Z et al. Neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting: a network meta-analysis. J. Natl Cancer Inst. 109, pii: djw217 (2017).
  Google Scholar
• 15 Navari RM, Qin R, Ruddy KJ et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 375, 134–142 (2016).
  Medline CASGoogle Scholar
• 16 Hu Z, Liang W, Yang Y et al. Personalized Estimate of chemotherapy-induced nausea and vomiting: development and external validation of a nomogram in cancer patients receiving highly/moderately emetogenic chemotherapy. Medicine (Baltimore) 95, e2476 (2016).
  Medline CASGoogle Scholar
• 17 Clemons M, Bouganim N, Smith S et al. Risk model-guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 2, 225–231 (2016).
  MedlineGoogle Scholar
• 18 Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Shelke AR. Biobehavioral factors in chemotherapy-induced nausea and vomiting. J. Natl Compr. Canc. Netw. 2, 501–508 (2004).
  MedlineGoogle Scholar